EP 42675
Alternative Names: EP42675; Org 42675Latest Information Update: 02 Oct 2015
Price :
$50 *
At a glance
- Originator Organon
- Developer Endotis Pharma
- Class Antithrombotics; Oligosaccharides
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 06 Dec 2009 Pharmacokinetics, pharmacodynamics and drug interactions data from two phase I trials in Healthy volunteers presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009) ,
- 19 May 2009 Adverse events data from phase I trials in healthy subjects released by Endotis Pharma
- 19 May 2009 Endotis Pharma completes its phase I programme in Thrombosis in Europe